Parkwood LLC Decreases Stock Holdings in Novo Nordisk A/S $NVO

Parkwood LLC lowered its stake in Novo Nordisk A/S (NYSE:NVO) by 65.5% during the second quarter, Holdings Channel.com reports. The fund owned 159,438 shares of the company’s stock after selling 303,133 shares during the quarter. Parkwood LLC’s holdings in Novo Nordisk A/S were worth $11,004,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in NVO. Revolve Wealth Partners LLC grew its position in shares of Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after purchasing an additional 200 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Novo Nordisk A/S by 15.6% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 261,243 shares of the company’s stock worth $18,141,000 after buying an additional 35,329 shares during the last quarter. Deutsche Bank AG increased its stake in Novo Nordisk A/S by 1.4% during the 1st quarter. Deutsche Bank AG now owns 150,634 shares of the company’s stock worth $10,460,000 after buying an additional 2,152 shares in the last quarter. Rathbones Group PLC raised its holdings in shares of Novo Nordisk A/S by 249.7% during the first quarter. Rathbones Group PLC now owns 42,006 shares of the company’s stock valued at $2,917,000 after acquiring an additional 29,993 shares during the last quarter. Finally, Dagco Inc. purchased a new position in shares of Novo Nordisk A/S in the first quarter valued at approximately $35,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

NVO has been the subject of several research reports. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $50.00 to $46.00 and set a “market perform” rating for the company in a research report on Tuesday, November 25th. Rothschild Redb raised shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 16th. HSBC reiterated a “hold” rating and issued a $54.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday. Rothschild & Co Redburn upgraded shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research report on Tuesday, September 16th. Finally, Dbs Bank upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Friday, August 22nd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Hold” and an average target price of $53.33.

Novo Nordisk A/S Trading Up 2.4%

Shares of NVO stock opened at $50.22 on Friday. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a twelve month low of $43.08 and a twelve month high of $111.17. The company’s 50-day moving average price is $51.05 and its 200-day moving average price is $58.57. The stock has a market cap of $224.23 billion, a price-to-earnings ratio of 14.60 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The firm had revenue of $11.79 billion during the quarter, compared to analysts’ expectations of $11.98 billion. As a group, equities analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.